Skip to main content

RT @doctorRBC: BE COMPLETE study: Bimekizumab (IL-17A and IL-17F inhibitor) efficacious in phase 3 trial for treatment o

Nov 13, 2022 3:40 pm
Social Author Name
Robert B Chao, MD
Tweet Content
BE COMPLETE study: Bimekizumab (IL-17A and IL-17F inhibitor) efficacious in phase 3 trial for treatment of PsA. No new safety signals. Abs#1599 @RheumNow #ACR22 https://t.co/iXj7wSRNeK
Show on Archive Page
On
Display in Search Results
On
PDQ
Off
×